Salt Lake City, United States
EVŌQ Bio has developed an inhaled therapeutic using EVQ-218 for the treatment of pulmonary bacterial infections in patients with cystic fibrosis. The company recently completed a successful Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration and is confidently advancing toward Phase I clinical trials.
EVŌQ MedTech integrates antimicrobial capabilities into medical devices to defend against a broad spectrum of contaminants like bacteria and fungi. The team is collaborating with leading catheter manufacturers with the aim of curbing healthcare-associated infections (HAIs), impacting more than 1 million hospital patients annually.
FUZE Technologies serves the textile, hospitality, fitness, and workspace industries. Its EPA-approved antimicrobial technology is free of chemicals, toxicity, and environmental waste. FUZE is working with some of the world’s most notable brands, including Nike, Adidas, the New England Patriots, Marriott, and Hilton. Founded in 2006, EVŌQ Nano operates within the Biotechnology, Medical Devices, and Pharmaceutical sectors. The company has not disclosed its last investment or the respective investors.
